[2] In clinical trials, patients taking tirzepatide (the active ingredient in Mounjaro) lost 22.5% of their weight in 72 weeks when combined with diet and exercise changes
Compared to other antidiabetic medications, including metformin, sulfonylurea, thiazolidinediones (TZDs), dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and insulins, GLP-1-RAs boast a combination of high efficacy in glycemic control, desirable function of weight loss, low risk of hypoglycemia, and even a mild benefit on the cardiovascular system
GLP-1 RAs also have potential benefits in patients with various neurological diseases independent of their glucose-modulating effect
For most users, the advantages of noticeable weight loss and better health far outweigh these minor annoyances
99% pure selective GLP-1 receptor agonist